Jeffrey Caughran, MD
Internal Medicine · Chattanooga, TNNPI 1700177482
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 49 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 13.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $929, more than ten times the $49 reported in 2019.
Across 49 payments — averaging $20.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$140
- Beone Medicines USA, Inc.$81
- Genentech USA, Inc.$75
- Novartis$67
- Johnson & Johnson$54
- Daiichi Sankyo Inc.$53
- plus $543 from 19 others
What the payments were for
- Food & beverage$1,011100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 8 | $140 |
| Beone Medicines USA, Inc. | 4 | $81 |
| Genentech USA, Inc. | 4 | $75 |
| Novartis | 3 | $67 |
| Johnson & Johnson | 3 | $54 |
| Daiichi Sankyo Inc. | 2 | $53 |
| Boehringer Ingelheim | 2 | $48 |
| Regeneron Healthcare Solutions, Inc. | 2 | $45 |
| Incyte Corporation | 2 | $42 |
| Immunocore Limited | 1 | $41 |
| E.r. Squibb & Sons, L.L.C. | 2 | $40 |
| Pfizer | 2 | $39 |
| Tersera Therapeutics LLC | 1 | $34 |
| GSK | 2 | $31 |
| Gilead | 1 | $26 |
| Merck | 1 | $24 |
| Spectrum Pharmaceuticals Inc. | 1 | $23 |
| Bristol Myers Squibb | 1 | $22 |
| Genmab U.S., Inc. | 1 | $22 |
| Array Biopharma Inc | 1 | $20 |
| Lilly USA, LLC | 1 | $20 |
| EMD Serono, Inc. | 1 | $20 |
| Rigel Pharmaceuticals, Inc. | 1 | $16 |
| Servier Pharmaceuticals LLC | 1 | $16 |
| Eisai Inc. | 1 | $15 |
How this compares
$1,011 in reported general payments places this provider in the 70th percentile of 2,216 internal medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CefuroximeCefuroxime Axetil | 11 | $113 |
| Atorvastatin Calcium | 15 | $73 |
| Prednisone | 20 | $70 |
| Carvedilol | 18 | $58 |
| ClopidogrelClopidogrel Bisulfate | 12 | $37 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Chattanooga
- Maighan SeagroveChattanooga$78K
- Carlton VollbergChattanooga$30K
- Jeremy HogstromChattanooga$30K
- Jermaine HogstromChattanooga$29K
- Eugene RyanChattanooga$26K
- John AndersonNashville$1.5M
- Tracie WalkerJackson$488K
- Nathan TrenthamEtowah$404K
- Dennis DeruelleKnoxville$263K
- Devin ShermanFranklin$191K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.